PEX
ProShares - Global Listed Private Equity ETF · Financial Services
21.65
0.69%(-0.15)
Close23.60
9.01%(+1.95)
After HoursLast Updated: — ET
52W L: $20.4952W H: $29.48
$21.65
CHG-0.17 (-0.78%)
H$22.34
L$20.49
VOL103K
PEX (1h)
ProShares - Global Listed Private Equity ETF · Financial Services
Three new license agreements signed and two research shipments completed in March 2026, spanning institutions in Australia, the United Kingdom, and Canada Toronto, Ontario--(Newsfile Corp. - April 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that Filament Health Corp. ("Filament") signed three new license agreements and completed two research shipments during March 2026, further expanding the global clinical network for PEX010, Filament's patented botanical psilocybin drug candidate. Red Light recently announced a definitive arrangement agreement to acquire Filament Health Corp., including its portfolio of 76 issued patents across 15 patent families and its lead drug candidate, PEX010.
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”).
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry Toronto, Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's Researgency.ai agentic artificial intelligence platform to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Filament"). The engagement will deploy Kala Bio's purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.
DEUTSCHE BANK AG\
10 percent owner
189,500 SH @ $7.77
2009-04-22
DEUTSCHE BANK AG\
10 percent owner
100,000 SH @ $7.36
2008-12-16
DEUTSCHE BANK AG\
10 percent owner
100,000 SH @ $7.36
2008-04-17
DEUTSCHE BANK AG\
10 percent owner
100,000 SH @ $7.35
2008-04-18
DEUTSCHE BANK AG\
10 percent owner
0 SH @ $0.00
2008-04-08
DEUTSCHE BANK AG\
10 percent owner
203,514 SH @ $6.00
2008-06-07
DEUTSCHE BANK AG\
10 percent owner
100,000 SH @ $7.35
2008-04-18
DEUTSCHE BANK AG\
10 percent owner
0 SH @ $0.00
2008-04-17